Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Add as a preferred source on Google
WALTHAM, Mass., March 01, 2018 -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences. The two conferences are:
- The Barclays Global Healthcare Conference at the Loews Hotel in Miami, Florida on Wednesday, March 14, 2018. Lonnie Moulder, CEO of TESARO, will participate in an analyst-led moderated Q&A from 2:35 to 3:00 PM ET and in meetings with investors.
- The Morgan Stanley Healthcare Corporate Access Day at the Boston Harbor Hotel in Boston, Massachusetts on Tuesday, March 20, 2018. Tim Pearson, EVP and CFO of TESARO, will participate in meetings with investors.
A live webcast of the presentation at the Barclays conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. Archived replays of these webcasts will be available on the Company’s website for 14 days following the conferences.
About TESARO
TESARO is an oncology-focused biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. For more information, visit www.tesarobio.com, and follow us on Twitter and LinkedIn.
For additional information, please contact:
Jennifer Davis
1.781.325.1116
[email protected]
